Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,797
archived clinical trials in
Peripheral Vascular Disease

Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2099
mi
from 98109
New Orleans, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2099
mi
from 98109
New Orleans, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1986
mi
from 98109
Opelousas, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1986
mi
from 98109
Opelousas, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1986
mi
from 98109
Opelousas, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1986
mi
from 98109
Opelousas, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1986
mi
from 98109
Opelousas, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1986
mi
from 98109
Opelousas, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1820
mi
from 98109
Shreveport, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1820
mi
from 98109
Shreveport, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1820
mi
from 98109
Shreveport, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1820
mi
from 98109
Shreveport, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2096
mi
from 98109
Slidell, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2096
mi
from 98109
Slidell, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1923
mi
from 98109
Winnsboro, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1923
mi
from 98109
Winnsboro, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2020
mi
from 98109
Zachary, LA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2020
mi
from 98109
Zachary, LA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2480
mi
from 98109
Portland, ME
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2480
mi
from 98109
Portland, ME
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis
2329
mi
from 98109
Baltimore, MD
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2318
mi
from 98109
Columbia, MD
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2318
mi
from 98109
Columbia, MD
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2475
mi
from 98109
Burlington, MA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2475
mi
from 98109
Burlington, MA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis
2502
mi
from 98109
Fall River, MA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis
2502
mi
from 98109
Fall River, MA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2473
mi
from 98109
Haverhill, MA
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2473
mi
from 98109
Haverhill, MA
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1903
mi
from 98109
Ann Arbor, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1903
mi
from 98109
Ann Arbor, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1888
mi
from 98109
Chelsea, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1888
mi
from 98109
Chelsea, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1931
mi
from 98109
Detroit, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1931
mi
from 98109
Detroit, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1889
mi
from 98109
Grand Blanc, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1889
mi
from 98109
Grand Blanc, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1816
mi
from 98109
Kalamazoo, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1816
mi
from 98109
Kalamazoo, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1842
mi
from 98109
Midland, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1842
mi
from 98109
Midland, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1907
mi
from 98109
Novi, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1907
mi
from 98109
Novi, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1767
mi
from 98109
Petoskey, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1767
mi
from 98109
Petoskey, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1922
mi
from 98109
Royal Oak, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1922
mi
from 98109
Royal Oak, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1922
mi
from 98109
Royal Oak, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1922
mi
from 98109
Royal Oak, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1861
mi
from 98109
Saginaw, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1861
mi
from 98109
Saginaw, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1793
mi
from 98109
Wyoming, MI
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1793
mi
from 98109
Wyoming, MI
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1392
mi
from 98109
Bloomington, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1392
mi
from 98109
Bloomington, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1411
mi
from 98109
Duluth, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1411
mi
from 98109
Duluth, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1390
mi
from 98109
Edina, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1390
mi
from 98109
Edina, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1389
mi
from 98109
Fridley, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1389
mi
from 98109
Fridley, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1391
mi
from 98109
Minneapolis, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1391
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1391
mi
from 98109
Minneapolis, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1391
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigator Site
1391
mi
from 98109
Minneapolis, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigator Site
1391
mi
from 98109
Minneapolis, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1386
mi
from 98109
Robbinsdale, MN
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1386
mi
from 98109
Robbinsdale, MN
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2067
mi
from 98109
Hattiesburg, MS
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2067
mi
from 98109
Hattiesburg, MS
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1974
mi
from 98109
Jackson, MS
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1974
mi
from 98109
Jackson, MS
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
2089
mi
from 98109
Picayune, MS
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
2089
mi
from 98109
Picayune, MS
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1611
mi
from 98109
Columbia, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1611
mi
from 98109
Columbia, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1504
mi
from 98109
Kansas City, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1504
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1504
mi
from 98109
Kansas City, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1504
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1504
mi
from 98109
Kansas City, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1504
mi
from 98109
Kansas City, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1717
mi
from 98109
Saint Louis, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1717
mi
from 98109
Saint Louis, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1638
mi
from 98109
Springfield, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1638
mi
from 98109
Springfield, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1638
mi
from 98109
Springfield, MO
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1638
mi
from 98109
Springfield, MO
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1267
mi
from 98109
Grand Island, NE
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1267
mi
from 98109
Grand Island, NE
Click here to add this to my saved trials
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
1350
mi
from 98109
Lincoln, NE
Cardiovascular Risk Reduction Study (Reduction in Recurrent Major CV Disease Events)
A Randomized, Double-blind, Placebo-controlled, Event-driven Trial of Quarterly Subcutaneous Canakinumab in the Prevention of Recurrent Cardiovascular Events Among Stable Post-myocardial Infarction Patients With Elevated hsCRP
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
1350
mi
from 98109
Lincoln, NE
Click here to add this to my saved trials